Hematology Clinical Trials

Statistical methods in hematology trials

The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.

All hematology trials

378 results

• CHOIRIndependent statistical analysis of the CHOIR trial, evaluating epoetin alfa in patients with anemia. Covers the randomized phase 4 design, composite primary endpoint, planned time-to-event analysis, and statistical interpretation.Phase 4n = 1,432NCT00211120
• Chronic Hepatitis C Virus Related Thrombocytopenia to Evaluate the Effects of E5501: Complete Statistical AnalysisIndependent statistical analysis of Chronic Hepatitis C Virus Related Thrombocytopenia to Evaluate the Effects of E5501: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 2Results postedn = 65NCT01355289
• Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Study: Complete Statistical AnalysisIndependent statistical analysis of Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 1Results postedn = 46NCT00978731
• Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 2Results postedn = 175NCT00923013
• Clinical Management of Argatroban in Patients With Heparin Induced Thrombocytopenia Type II: Complete Statistical AnalysisIndependent statistical analysis of Clinical Management of Argatroban in Patients With Heparin Induced Thrombocytopenia Type II: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 2Results postedn = 20NCT00861692
• Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 1/2Results postedn = 93NCT01471782
• Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03646123).Phase 2Results postedn = 255NCT03646123
• CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1a): Complete Statistical AnalysisIndependent statistical analysis of CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1a): primary endpoint results, effect estimate with confidence interval, sample-size…Phase 3Results postedn = 787NCT01010061
• Clofarabine and Cytarabine in Treating Patients With Acute Myeloid Leukemia With Minimal Residual Disease: Complete Statistical AnalysisIndependent statistical analysis of Clofarabine and Cytarabine in Treating Patients With Acute Myeloid Leukemia With Minimal Residual Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 2Results postedn = 2NCT00863434
• Clofarabine for Myelodysplastic Syndrome (MDS) Patients Who Failed Vidaza Treatment (tx): Complete Statistical AnalysisIndependent statistical analysis of Clofarabine for Myelodysplastic Syndrome (MDS) Patients Who Failed Vidaza Treatment (tx): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 2Results postedn = 10NCT00700011
• Clofarabine in Treating Patients With T-Cell or Natural Killer-Cell Non-Hodgkin’s Lymphoma That Has Relapsed or Not Responded to Previous Treatment: Complete Statistical AnalysisIndependent statistical analysis of Clofarabine in Treating Patients With T-Cell or Natural Killer-Cell Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment: primary endpoint results, effect estimate with confidence interval,…Phase 1/2Results postedn = 29NCT00416351
• Clofarabine Plus Low-Dose Cytarabine Induction and Decitabine Consolidation in Frontline Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS): Complete Statistical AnalysisIndependent statistical analysis of Clofarabine Plus Low-Dose Cytarabine Induction and Decitabine Consolidation in Frontline Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS): primary endpoint results, effect estimate with confidence interval, sample-size…Phase 2Results postedn = 122NCT00778375
• Cognitive Stimulation Therapy for Dementia: A Two-Armed Pragmatic Trial: Complete Statistical AnalysisIndependent statistical analysis of Cognitive Stimulation Therapy for Dementia: A Two-Armed Pragmatic Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05860127).Phase NAResults postedn = 133NCT05860127
• Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.: Complete Statistical AnalysisIndependent statistical analysis of Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 2Results postedn = 107NCT00390793
• Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Burkitt’s Lymphoma or Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 2Results postedn = 23NCT00133991
• Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 3Results postedn = 1,895NCT00408005
• Combination of GTI-2040 and Cytarabine in the Treatment of Refractory and Relapsed Acute Myeloid Leukemia (AML): Complete Statistical AnalysisIndependent statistical analysis of Combination of GTI-2040 and Cytarabine in the Treatment of Refractory and Relapsed Acute Myeloid Leukemia (AML): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 2Results postedn = 27NCT00565058
• Combination Study of IPH2201 (Monalizumab) With Ibrutinib in Relapsed, Refractory or Previously Untreated CLL: Complete Statistical AnalysisIndependent statistical analysis of Combination Study of IPH2201 (Monalizumab) With Ibrutinib in Relapsed, Refractory or Previously Untreated CLL: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 1/2Results postedn = 22NCT02557516
• Combined Immunochemotherapy Followed By Reduced Dose Radiation Therapy (RT) for Patients With Newly Diagnosed Primary Central Nervous System Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Combined Immunochemotherapy Followed By Reduced Dose Radiation Therapy (RT) for Patients With Newly Diagnosed Primary Central Nervous System Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size…Phase NAResults postedn = 52NCT00594815
• Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation: Complete Statistical AnalysisIndependent statistical analysis of Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 2Results postedn = 6NCT04281498
• Combined T Cell Depleted Haploidentical Peripheral Blood Stem Cell and Unrelated Umbilical Cord Blood Transplantation in Patients With Hematologic Malignancies Using a Total Lymphoid Irradiation Based Preparative Regimen: Complete Statistical AnalysisIndependent statistical analysis of Combined T Cell Depleted Haploidentical Peripheral Blood Stem Cell and Unrelated Umbilical Cord Blood Transplantation in Patients With Hematologic Malignancies Using a Total Lymphoid Irradiation Based Preparative Regimen:…Phase 2Results postedn = 24NCT02199041
• Common Safety Follow-up Trial of Tecemotide (L-BLP25): Complete Statistical AnalysisIndependent statistical analysis of Common Safety Follow-up Trial of Tecemotide (L-BLP25): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01423760).Phase NAResults postedn = 27NCT01423760
• Comparing the Availability of AQ280 in the Body After Single Oral Doses of a Capsule Formulation Versus a Tablet for Oral Suspension Formulation: Complete Statistical AnalysisIndependent statistical analysis of Comparing the Availability of AQ280 in the Body After Single Oral Doses of a Capsule Formulation Versus a Tablet for Oral Suspension Formulation: primary endpoint results, effect estimate…Phase 1Results postedn = 9NCT07093008
• Comparison of Fluconazole vs Voriconazole to Treat Fungal Infections for Blood and Marrow Transplants (BMT CTN 0101): Complete Statistical AnalysisIndependent statistical analysis of Comparison of Fluconazole vs Voriconazole to Treat Fungal Infections for Blood and Marrow Transplants (BMT CTN 0101): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 3Results postedn = 600NCT00075803
• Consolidation Therapy for Acute Myeloid Leukemia Guided by Leukemia Stem Cell Behavior: Complete Statistical AnalysisIndependent statistical analysis of Consolidation Therapy for Acute Myeloid Leukemia Guided by Leukemia Stem Cell Behavior: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 2/3Results postedn = 10NCT01588951
• CORALA statistical analysis of the CORAL phase 3 trial comparing R-ICE versus R-DHAP in patients aged 18–65 with relapsed diffuse large B-cell lymphoma. Includes trial design, endpoints, planned statistical methods, and interpretation…Phase 3n = 481NCT00137995
• CPIT001Independent statistical analysis of Check Point Inhibition After Autologous Stem Cell Transplantation in Patients at High Risk of Post Transplant Recurrence: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 1/2Results postedn = 46NCT02681302
• CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients: Complete Statistical AnalysisIndependent statistical analysis of CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients: primary endpoint results, effect estimate with confidence interval,…Phase 2Results postedn = 60NCT04195945
• CRISTALLOIndependent statistical analysis of A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT…Phase 3Results postedn = 166NCT04285567
• CTREPHIndependent statistical analysis of Efficacy and Tolerability of Subcutaneously Administered Treprostinil Sodium in Patients With Severe (Non-operable) Chronic Thromboembolic Pulmonary Hypertension (CTREPH): primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 3Results postedn = 105NCT01416636
• Curcumin and Cholecalciferol in Treating Patients With Previously Untreated Stage 0-II Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Curcumin and Cholecalciferol in Treating Patients With Previously Untreated Stage 0-II Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 2Results postedn = 35NCT02100423
• Cyclophosphamide, Carfilzomib, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Active Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Cyclophosphamide, Carfilzomib, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Active Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 1/2Results postedn = 64NCT01057225
• Cyproheptadine Hydrochloride and Nutritional Supplementation in Treating Young Patients With Weight Loss With Cancer: Complete Statistical AnalysisIndependent statistical analysis of Cyproheptadine Hydrochloride and Nutritional Supplementation in Treating Young Patients With Weight Loss With Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 2Results postedn = 9NCT00949117
• Daily Versus Alternate Day Iron Supplementation for the Treatment of Iron Deficiency Anemia in Pregnancy: Complete Statistical AnalysisIndependent statistical analysis of Daily Versus Alternate Day Iron Supplementation for the Treatment of Iron Deficiency Anemia in Pregnancy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 4Results postedn = 14NCT04594070
• Daprodustat Bioequivalence and Food Effect Study: Complete Statistical AnalysisIndependent statistical analysis of Daprodustat Bioequivalence and Food Effect Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03493386).Phase 1Results postedn = 64NCT03493386
• Daratumumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome: Complete Statistical AnalysisIndependent statistical analysis of Daratumumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 2Results postedn = 7NCT03067571
• Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab: Complete Statistical AnalysisIndependent statistical analysis of Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 2Results postedn = 88NCT03871829
• DASISIONIndependent statistical analysis of the DASISION phase 3 trial of dasatinib versus imatinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia, including trial design, complete cytogenetic response, time-to-event analyses, statistical methodology,…Phase 3Results postedn = 547NCT00481247
• Decision Aid for Therapeutic Options In Sickle Cell Disease: Complete Statistical AnalysisIndependent statistical analysis of Decision Aid for Therapeutic Options In Sickle Cell Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02326597).Phase NAResults postedn = 134NCT02326597
• Decision Making Tool for Firearm Storage: Complete Statistical AnalysisIndependent statistical analysis of Decision Making Tool for Firearm Storage: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT06382194).Phase NAResults postedn = 5NCT06382194
• Decitabine and Clofarabine in Higher Risk Myelodysplastic Syndromes (MDS): Complete Statistical AnalysisIndependent statistical analysis of Decitabine and Clofarabine in Higher Risk Myelodysplastic Syndromes (MDS): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00903760).Phase 2Results postedn = 42NCT00903760
• Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-risk Myelodysplastic Syndrome: Complete Statistical AnalysisIndependent statistical analysis of Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-risk Myelodysplastic Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 2Results postedn = 71NCT00968071
• Decitabine and Tretinoin in Treating Patients With Myelodysplastic Syndromes: Complete Statistical AnalysisIndependent statistical analysis of Decitabine and Tretinoin in Treating Patients With Myelodysplastic Syndromes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00382200).Phase 1/2Results postedn = 54NCT00382200
• Decitabine Followed by Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory AML and MDS: Complete Statistical AnalysisIndependent statistical analysis of Decitabine Followed by Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory AML and MDS: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 2Results postedn = 7NCT01607645
• Defibrotide TMA Prophylaxis Pilot Trial: Complete Statistical AnalysisIndependent statistical analysis of Defibrotide TMA Prophylaxis Pilot Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03384693).Phase 2Results postedn = 25NCT03384693
• Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 1/2Results postedn = 11NCT03035331
• Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome: Complete Statistical AnalysisIndependent statistical analysis of Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01165996).Phase 1/2Results postedn = 25NCT01165996
• Does IV Acetaminophen Reduce Opioid Requirement in Pediatric Patients With Acute Sickle Cell Crises?: Complete Statistical AnalysisIndependent statistical analysis of Does IV Acetaminophen Reduce Opioid Requirement in Pediatric Patients With Acute Sickle Cell Crises?: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 4Results postedn = 71NCT03541980
• Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene: Complete Statistical AnalysisIndependent statistical analysis of Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 1/2Results postedn = 3NCT01875237
• Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell Transplantation: Complete Statistical AnalysisIndependent statistical analysis of Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell Transplantation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 2Results postedn = 17NCT02458235

← All therapeutic areas